Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Find generic entry opportunities
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Lung surfactant compositions|
|Abstract:||A synthetic protein-free lung surfactant composition is utilized to temporarily substitute for natural lung surfactant in the mammalian lung where such natural lung surfactant is absent or in low concentration. The synthetic surfactant composition consists essentially of a major amount of 1,2-dipalmitoyl-sn-3-glycerophosphoryl choline (DPPC), and a minor amount of a fatty alcohol, preferably a fatty alcohol having from 14 to 18 carbon atoms, and especially n-hexdecan-1-ol. The synthetic surfactant composition is administered directly into the lungs of a distressed subject to create a film on the alveolar interfacial surfaces and reduce surface tension. Expansion of the alveolar spaces is thereby facilitated.|
|Inventor(s):||Clements; John A. (Tiburon, CA)|
|Assignee:||Regents of the University of California (Berkeley, CA)|
Patent Claim Types:|
see list of patent claims
|Composition; Formulation; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Canada||1184503||<disabled in preview>|
|Czechoslovakia||9103849||<disabled in preview>|
|Germany||3164207||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.